This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.
Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen registry / M. Filippini, C. Bazzani, F. Atzeni, P. Sarzi Puttini, A. Marchesoni, E.G. Favalli, R. Caporali, L. Cavagna, R. Gorla. - In: BIOMED RESEARCH INTERNATIONAL. - ISSN 2314-6133. - 2014:(2014 Jul), pp. 416892.1-416892.8. [10.1155/2014/416892]
Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen registry
P. Sarzi Puttini;E.G. Favalli;R. Caporali;
2014
Abstract
This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.
| File | Dimensione | Formato | |
|---|---|---|---|
|
416892.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.38 MB
Formato
Adobe PDF
|
1.38 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
